CINECA IRIS Institutional Research Information System

AGATE, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.960
EU - Europa 5.242
AS - Asia 1.388
AF - Africa 259
SA - Sud America 39
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.899
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.827
DE - Germania 2.041
IT - Italia 1.021
SE - Svezia 817
CN - Cina 604
GB - Regno Unito 462
SG - Singapore 367
BG - Bulgaria 270
AT - Austria 219
CI - Costa d'Avorio 146
RU - Federazione Russa 131
CA - Canada 127
TR - Turchia 127
SN - Senegal 104
VN - Vietnam 99
UA - Ucraina 73
FI - Finlandia 69
IN - India 61
HK - Hong Kong 44
CH - Svizzera 31
BE - Belgio 22
IR - Iran 19
BR - Brasile 16
JP - Giappone 16
NL - Olanda 16
FR - Francia 13
CZ - Repubblica Ceca 10
PL - Polonia 10
AU - Australia 9
IL - Israele 7
KR - Corea 7
TW - Taiwan 7
CL - Cile 6
IE - Irlanda 6
PH - Filippine 6
GR - Grecia 5
ID - Indonesia 5
AR - Argentina 4
CO - Colombia 4
LT - Lituania 4
MX - Messico 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
AZ - Azerbaigian 3
EC - Ecuador 3
MY - Malesia 3
RS - Serbia 3
VE - Venezuela 3
BJ - Benin 2
BY - Bielorussia 2
EG - Egitto 2
ES - Italia 2
HU - Ungheria 2
IQ - Iraq 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
ZA - Sudafrica 2
A1 - Anonimo 1
AE - Emirati Arabi Uniti 1
DK - Danimarca 1
DZ - Algeria 1
EU - Europa 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MA - Marocco 1
MN - Mongolia 1
NG - Nigeria 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 12.899
Salva come PNG Salva come JPEG
Città #
Woodbridge 658
Chandler 580
Santa Clara 540
Fairfield 490
Ann Arbor 403
Ashburn 394
Milan 357
Houston 304
Sofia 270
Seattle 214
Wilmington 208
Vienna 203
New York 196
Singapore 187
Cambridge 181
Beijing 180
Abidjan 146
Princeton 138
Boardman 128
London 107
Lawrence 106
Ottawa 106
Dakar 104
Florence 91
Jacksonville 91
Serra 85
Medford 80
Frankfurt am Main 64
Nanjing 58
Pisa 57
Izmir 56
Bremen 52
Dearborn 52
Istanbul 52
Des Moines 51
Boulder 50
Dong Ket 49
Rome 41
San Diego 37
Munich 35
Redmond 34
Fuzhou 33
Hong Kong 32
Shanghai 31
Lancaster 28
Bern 27
Los Angeles 26
Redwood City 25
Ogden 24
Brussels 21
Nanchang 20
Washington 20
Guangzhou 18
Quanzhou 18
Jiaxing 16
Kunming 16
Dallas 14
Jüchen 13
Changsha 12
Toronto 12
Helsinki 11
Ningbo 11
Norwalk 11
Zhengzhou 11
Chiesina Uzzanese 10
Düsseldorf 10
Hefei 10
Nürnberg 10
Shenyang 10
Vicopisano 10
Wuhan 10
Brno 9
Chengdu 9
Kocaeli 9
Pune 9
Tianjin 9
Hangzhou 8
Hebei 8
Philadelphia 8
Phoenix 8
Scandicci 8
Jinan 7
Falls Church 6
Grafing 6
Xiamen 6
Chicago 5
Genoa 5
Lucca 5
Pontedera 5
Salt Lake City 5
Samsun 5
San Francisco 5
Urmia 5
Amsterdam 4
Bratislava 4
City of Westminster 4
Dublin 4
Edinburgh 4
Marseille 4
Matsudo 4
Totale 7.933
Salva come PNG Salva come JPEG
Nome #
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 202
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 201
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 199
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 197
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 192
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 184
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 182
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 178
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 172
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 171
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 169
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 164
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 162
Targeted Therapy in Thyroid Cancer: State of the Art 161
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 158
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 156
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 156
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 155
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 153
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 152
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 148
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 147
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 147
null 146
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 146
RET point mutations in Thyroid Carcinoma 144
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 143
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 143
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 136
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 136
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 134
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 133
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 131
Il carcinoma tiroideo: nuove prospettive terapeutiche. 129
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 129
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 128
Thyroid consequences of the Chernobyl nuclear accident. 128
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 128
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 128
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 127
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 127
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 126
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 125
null 122
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 122
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 121
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 121
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 120
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 119
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 119
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 119
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 117
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 116
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 116
Thyroid incidentaloma 115
null 114
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 113
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 113
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 113
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 111
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 111
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 109
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 107
null 107
null 105
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 105
null 103
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 102
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 101
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 101
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 100
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 99
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 97
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 97
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 95
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 94
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 92
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 91
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 90
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 90
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 90
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 88
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 87
null 86
null 84
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 82
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 76
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 74
null 70
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 69
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 68
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 67
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 67
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 67
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 65
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 63
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 62
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 61
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 60
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 59
Totale 12.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.486
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.486
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.444 0 0 0 0 0 254 249 113 151 270 374 33
2020/2021912 154 39 143 28 49 84 47 54 57 82 45 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.398 280 390 203 186 209 246 44 171 476 21 157 15
2023/20241.601 161 174 220 110 214 283 114 52 28 22 71 152
2024/20251.306 47 157 44 268 487 303 0 0 0 0 0 0
Totale 13.151